Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
The primary objectives of this study is to compare the efficacy of paclitaxel monotherapy with irinotecan monotherapy as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first line therapy.
Gastric Cancer
DRUG: Paclitaxel|DRUG: Irinotecan
progression-free survival, Tumor evaluation using RECIST v1.1, every 8 weeks
Safety, Number of Participants and toxicity grade accordong to NCI-CTCAE v3.0 as a Measure of Safety, up to 4 weeks after last administration of chemotherapy|Overall survival, 1 year
The primary objectives of this study is to compare the efficacy of paclitaxel monotherapy with irinotecan monotherapy as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first line therapy.